Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

Status unconfirmed · Phase 4

Conditions studied: Chronic Hepatitis C

In brief

This study is evaluating the safety and efficacy of a 12 week treatment LDV/SOF FDC in patients with Chronic GT1 or GT4 HCV infection and autoimmune disease

Key facts

Study ID

NCT02691728

Run by

Peter J. Ruane, M.D., Inc.

People needed

40

Starts

2016-02-01

Expected to finish

2017-05-01

Last updated by the study team

2016-02-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Chronic GT1 or GT4 HCV Infection
• Diagnosed with autoimmune disease (rheumatoid arthritis, psoriatic arthritis, lupus, etc.) and is currently receiving treatment for the condition.

You may not qualify if…

• Infection with HIV or HBV

Where it is running

• Peter J. Ruane, MD, Inc. — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.